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In this study, we show how light can be absorbed by the body of a living rat due to an injected pigment circulating in the blood
stream. This process is then physiologically translated in the tissue into a chemical signature that can be perceived as an image
by magnetic resonance imaging (MRI). We previously reported that illumination of an injected photosynthetic
bacteriochlorophyll-derived pigment leads to a generation of reactive oxygen species, upon oxygen consumption in the
blood stream. Consequently, paramagnetic deoxyhemoglobin accumulating in the illuminated area induces changes in image
contrast, detectable by a Blood Oxygen Level Dependent (BOLD)-MRI protocol, termed photosensitized (ps)MRI. Here, we show
that laser beam pulses synchronously trigger BOLD-contrast transients in the tissue, allowing representation of the luminous
spatiotemporal profile, as a contrast map, on the MR monitor. Regions with enhanced BOLD-contrast (7-61 fold) were deduced
as illuminated, and were found to overlap with the anatomical location of the incident light. Thus, we conclude that luminous
information can be captured and translated by typical oxygen exchange processes in the blood of ordinary tissues, and made
visible by psMRI (Fig. 1). This process represents a new channel for communicating environmental light into the body in certain
analogy to light absorption by visual pigments in the retina where image perception takes place in the central nervous system.
Potential applications of this finding may include: non-invasive intra-operative light guidance and follow-up of photodynamic
interventions, determination of light diffusion in opaque tissues for optical imaging and possible assistance to the blind.
Citation: Tempel-Brami C, Pinkas I, Scherz A, Salomon Y (2007) Detection of Light Images by Simple Tissues as Visualized by Photosensitized
Magnetic Resonance Imaging. PLoS ONE 2(11): e1191. doi:10.1371/journal.pone.0001191
INTRODUCTION
Magnetic Resonance Imaging (MRI) is an established, powerful,
noninvasive method for tomography of otherwise opaque tissues
[1,2]. While optical imaging techniques are limited by tissue
depth, due to absorption, light scattering and photon diffusion
processes [3], the study of light diffusion in opaque tissues may
now be facilitated based-on the detection of luminosity by Blood
Oxygen Level Dependent (BOLD)-MRI, as shown below.
BOLD-MRI provides monitoring of acute changes in tissue
oxygenation status, endowing spatiotemporal information [4], as
routinely performed in functional fMRI during neuroimaging
([5,6] and references therein). This technique, based on the
magnetic properties of endogenous deoxyhemoglobin (deoxyHb),
enables rapid readouts of the dynamic balance between circulating
paramagnetic deoxyHb and diamagnetic oxyHb. Image contrast
of BOLD-MRI may also be affected by blood flow, carbon dioxide
tension, hematocrit, pH or the presence of biphosphoglycerate [7].
Applications of BOLD-MRI include evaluation of tissue oxygen
levels [8], studies of angiogenesis [9] and evaluation of
pathological ischemia in the kidney [10], brain [11] and heart
[12]. In other applications, like neuroimaging [5,6], hypercapnia/
hyperoxia studies [13], and Vascular Targeted Photodynamic
Therapy (VTP) [14], BOLD MRI-contrast is artificially manip-
ulated. In VTP, an externally triggered localized photochemical
process generates reactive oxygen species (ROS) in the circulation,
inducing focal deoxyHb accumulation and BOLD contrast [14]
upon oxygen [15] consumption.
Vascular Targeted Photodynamic Therapy is a local treatment
modality used to ablate solid tumors upon focal illumination of
tumor-bearing animals pretreated with a photosensitizer drug. This
treatment involves intravenous injection/infusion of Pd-bacterio-
chlorophyll derivatives [16] (e.g. WST09 [14,17–21], or WST11
[22,23]) as photosensitizing drugs, followed by immediate local
transdermal or interstitial illumination provided by optic-fiber at
matched near-infrared wavelengths (763 or 755nm respectively).
Consequently, cytotoxic ROS (mainly superoxide and hydroxyl
radicals [24]) are generated in the tumor vasculature, resulting in
acute vascular occlusion and blood stasis, development of necrosis
and tumor eradication. This therapeutic modality is presently in
phase II clinical trials for prostate cancer therapy, in collaboration
with Steba-Biotech and Negma France [18].
This study describes how an illuminated tissue and the
photochemistry involved in VTP can act together as a detector-
screen to translate a spatiotemporal light profile into paramagnetic
information imaged by psMRI (Fig. 1). This detector-screen
consists of the photo-excited pigment that circulates in the blood
vessel network, driving an oxygen-exchange cascade, which
culminates with image mapping of light dependent deoxyhemo-
globin distribution. The performance of the detector-screen is
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implications are discussed, and possible practical applications of
this new imaging concept are suggested.
RESULTS
We hypothesized that if a pigment-treated animal is illuminated,
the luminous incident-image displayed on the animal tissue can be
translated in vivo into a deoxyHb-dependent BOLD-MRI contrast
map, reproducing its spatiotemporal profile. A laser beam
(755 nm) was directed at a subcutaneous (s.c.) tumor, grafted to
the thigh of a rat, which was placed in the MRI magnet (Fig. 1,
Fig. 2). Following the pretreatment (PC) and light (LC) control
scans, the animal was i.v. injected with WST11 and the tumor was
illuminated by an alternate light:dark (12 s:110 s) sequence
paradigm (P1). Decreases in MR signal intensity, due to local
deoxyHb accumulation, were used to create maps of the BOLD-
contrast changes, relative to the PC baseline (see methods). Well-
defined BOLD-contrast activation spikes (7–8% higher than PC)
demonstrating synchrony with the illumination paradigm were
instantaneously observed, while BOLD-contrast reverted to the
baseline values during the intervening dark phases, where
DeoxyHb was apparently washed out upon re-oxygenation
(Fig. 2A). No contrast changes were observed in the PC and LC.
Processing of the collected data into a BOLD-MRI contrast
map (for example at 6 min, 2nd pulse, Fig. 2B), overlaid onto the
anatomic image (Fig. 2C), appeared to represent the boundaries of
the incident display rather poorly, most likely due to low signal to
noise ratio, motion or detector-screen artifacts. To overcome this
problem, all 60 sequential BOLD activation maps collected were
processed into a single map, termed the correlation map. This
map was obtained by computing the temporal correlation between
BOLD activation and the illumination sequence paradigm
(p,0.02), on a pixel-by-pixel basis (see Methods). Pixels whose
BOLD contrast responded in synchrony with the illumination
paradigm were identified, as illuminated. Repetition of the 12 s
light pulses progressively contributed to the image quality and to
the reduction of the surrounding noise, as shown for the first three
light pulses (Fig. 2D–F). The final correlation map presents pixel
clusters which allow deduction of the illuminated zone that
overlapped with the anatomic location of the incident light, as
determined with the aiming laser beam (Fig. 2G, white circle).
Relative to the surrounding area, this zone demonstrated
Figure2.TemporalcorrelationbetweenilluminationandBOLD-contrast
changes. A. Time-course of the BOLD response in the deduced illuminated
area (white circle in G). The first 4 min included the pretreatment (PC) and
the light control (LC) pulses (200 mW/cm
2). Each time point corresponds
to a 12 s T2* BOLD-sensitive image. Black arrow indicates WST11 injection
to begin photosensitization, using an alternating light:dark sequence
(12 s:110 s), paradigm P1 (red bars). B. Percent BOLD activation map at
t=6.4 min, overlaid on the anatomic image, C. C. MRI coronal view of the
rat thigh, s.c. grafted with MADB106 tumor. A light beam (w 1 cm) was
projected onto the tumor area. The white dotted circle depicts the tumor.
D–F. Correlation coefficient maps (p,0.02) obtained after the 1
st,2
nd and
3
rd light pulses respectively,overlaid on theanatomic image. G. Correlation
coefficient map of the entire paradigm (60 images) overlaid on the
anatomy, allowing deduction of the illuminated field on the psMR image
(white circle) that spatially overlaps with the incident light. The colored
pixel clusters represent high blood vessel densities and/or larger vessels in
the illuminated zone; while the dark areas represent low/no vascularity.
The contrast enhancement ratio of illuminated relative to the surrounding
areas was 49-fold (average 33623SD, n=8). H. Gd-DTPA contrast
enhanced imaging (20 min post-treatment) marks functional, permeable
blood vessels. The inset shows the correlation map overlaid on the
GdDTPA enhanced image. Note: non-illuminated vasculature is not visible
on the correlation map (compare red arrows in G versus H). Dashed white
circles represent copies of the white circle in G. BOLD-contrast scale bar
relates to (B) and correlation scale bar to (D–G).
doi:10.1371/journal.pone.0001191.g002
Figure 1. Schematic view of the experimental set up for in-vivo
translation of light into an MR-image. The laser pulses are projected
onto the pigment-treated animal placed inside the MRI magnet. The
illuminated display is physiologically translated in the tissue into
a chemical signature and reproduced as an image on the MRI monitor.
doi:10.1371/journal.pone.0001191.g001
BOLD View of Light
PLoS ONE | www.plosone.org 2 November 2007 | Issue 11 | e1191a significantly positive contrast enhancement ratio of 49-fold in
this experiment (average 33623SD, n=8), whereby false-positive
pixels were barely detectable (0.6%, average 1%60.4SD). The
non-uniform distribution of the pixel clusters within the illumi-
nated region may reflect variations in tumor vascular density, as
independently verified by GdDTPA-contrast-enhanced MRI of
the tumor’s vascular functionality. The enhanced pixels of the
correlation map, which lie within the illuminated display (white
circle Fig. 2H & insert), indeed coincide with the tumor vascular
pattern, as confirmed by GdDTPA contrast-enhanced MRI.
However, GdDTPA-enhanced areas outside the deduced illumi-
nated zone (red arrow) were not identified in the correlation map
(compare red arrows in Figs. 2 G&H). Thus, psMRI features the
unique ability to detect and differentiate illuminated, from non-
illuminated vascular regions. Additionally, the synchrony between
the BOLD response pattern and the pulsed light paradigm
illustrates the reversible nature of the photosensitization process
(Fig. 2A). Although GdDTPA-enhanced imaging demonstrated
vascular functionality at the treatment site following the eight
consecutive 12 s light pulses (Fig. 2H), 90% tissue necrosis was
histologically observed in the tumor 24 h later (not shown). Yet,
negligible necrosis was observed following a single 12 s light pulse
of 200 mW/cm
2 (2.4 J/cm
2), equivalent to 0.6–4% of the light
dose routinely used in standard therapeutic VTP protocols (60–
360 J/cm2) used to induce acute, irreversible blood stasis before
the end of the treatment [25,26]. The gradual decline in spike
height seems to reflect WST11 clearance and possibly develop-
ment of vascular photo-damage (Fig. 2H). No significant
correlation was found when the BOLD contrast results were
tested against delayed illumination paradigms, eliminating the
possibility of a random or deferred relationship.
The non-uniform vascular pattern of the tumor was found to
dominate the BOLD activation map, creating a detector-screen
artifact that interfered with the recognition of the spatiotemporal
profile of the incident light beam. To improve the performance of
the tissue as a detector screen we chose a different model, where
a light beam was directed onto healthy, striated muscle tissue in
the rat thigh. This tissue contains a rich, uniform vascular matrix.
Light beams with a circular, or kite-shaped cross-section were
created by placing respective masks in the light path (Figs. 3 A&E).
In these experiments, we used a 10 min illumination paradigm, P2
(55 mW/cm
2, 33 J/cm
2, Fig. 2J). As in the tumor model, the
anatomic location of these light fields were fully ascertainable by
the correlation maps (Figs. 3 C&G), calculated from the BOLD-
contrast maps (Figs. 3 B&F). The contrast enhancement ratio of
the deduced illuminated areas was 2362SD (n=3) fold higher
than in the respective non-illuminated surroundings. These results
suggest that when detector uniformity increases, as in the case of
the capillary bed of striated muscle tissue, the accuracy of the
psMRI image increases. While image location coincided with the
incident light, deviations from the circular shape of the display
were observed on the psMR image (Fig. 3C). This was probably
related to a downstream effect of deoxyHb. The magnified size of
the registered images, relative to the original, may stem from
inherent photon diffusion and tissue light scattering. A slight
degree of photo-damage, marked by edema and scattered
Figure 3. Shape-recognition of illumination field by BOLD-contrast changes: P2 paradigm. Homogeneous light (55 mW/cm
2) was delivered via
a diffuser onto the rat thigh. With the use of respective masks the light beam-cross section was circular (w 1.6 cm, A–D) or kite-shaped (0.6 cm length,
E–H). B&F. Representative BOLD-contrast activation maps acquired at the end of the photosensitization phase are overlaid on the anatomic image
and D&G. are the respective correlation coefficient maps (p,0.02). Colored pixel clusters on the anatomic image outline the deduced shape of the
light field. Contrast enhancements of the deduced circle and the kite shapes were respectively 21 and 24-fold higher than their neighboring
surroundings. D&H. Locations and shapes of the projected light fields on the respective anatomic images are deduced from the above correlations
(white shapes). I. The BOLD-MRI protocol, using an acquisition time of 25 s/image yielded a total of 45 (A–D) or 40 images (E–H). J. Paradigm P2
consists of a single 10 min illumination. PI=Post-illumination.
doi:10.1371/journal.pone.0001191.g003
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illumination. However, it should be noted that the vasculature of
normal healthy tissues is generally less sensitive to VTP, as
compared to tumor tissue [19].
DISCUSSION
This study provides evidence that a luminous display, projected
onto tissues of animals treated with a photosensitizer, can be
captured, viewed and recognized by psMRI. Furthermore, it is
possible to distinguish illuminated from non-illuminated blood
vessels (Fig. 2), due to endogenous deoxyHb and its reactivity in
the illuminated regions. Under the conditions used, an increase in
signal to noise ratio of the correlation maps was gained with
increased light pulse number, improving the clarity of the psMR
image. In contrast, a decline in the correlation values was observed
at the same time (Fig. 2 D–G), possibly due to accumulating
biological effects (sensitizer clearance and/or photo-damage); this
will have to be considered when programming future stimulation
paradigms. It is anticipated that by manipulation local phototox-
icity, forthcoming improvement of experimental conditions,
optimization of MRI and better image processing algorithms can
reduce the light pulse energy requirements for its imaging. These
improvements will provide an increase in the efficiency of BOLD
contrast recording and, subsequently, minimize, or fully eliminate
imaging-associated vascular damage. In the case of the therapeutic
VTP protocol, whereby target tissue destruction is the objective,
damage contributed by simultaneous psMR imaging becomes
irrelevant. These predictions are compatible with previous findings
in our lab, which demonstrated reversible enzymatic and cellular
processes induced by low levels of photosensitized ROS at
nondestructive, physiological conditions [27].
When comparing the basis of a BOLD contrast response in
psMRI and fMRI, a few points must be considered. Although the
response to the light signal is instantaneous in psMRI, the response
to neuronal stimulation by fMRI is delayed [28,29]. This stems
from the fact that in psMRI, deoxyHb accumulation is coupled to
oxygen consumption by photon-capture of the sensitizer and
diffusion-limited dissociation of oxyHb. In contrast, in fMRI-based
neuroimaging, deoxyHb accumulation is coupled to stimulation by
neuronal input via metabolic consumption of oxygen with a slower
hemodynamic response that develops in a matter of seconds.
Insummary,the displayed incident imageiscapturedbythe tissue
as an invisible chemical signature, represented by the spatiotemporal
distribution of photogenerated deoxyHb. The dynamic presentation
by psMRI of a BOLD contrast map permits recognition of the
originalincidentdisplay,inanalogytovisualperceptionbythebrain.
The quality of the psMR image is affected by the density and
uniformity of the vascular detector-screen (Fig. 3). Furthermore, it is
suggested that living organisms have the capacity to detect such light
imprintedimages,byacirculatingdetector-pigment(administeredor
ingested) in tandem with de-saturation of ubiquitous Hb, in
a reaction that is unrelated to the visual process. The question of
whether endogenous pigments in animals may reflect on environ-
mental luminosity, in a similar manner, as a mode of light detection,
remains open. Preliminary results show promising results in the
acquisition and imaging of three-dimensional optical information
from the vascular detector screen by psMRI.
We envisage psMRI as a means of tracking BOLD contrast
changes, following sub-lethal photosensitization in normal tissues,
where reduced photo-damage is expected. Immediate applications
of this phenomenon may include intra-operative light guidance
and a follow-up of photodynamic interventions, as well as a unique
option for investigating light diffusion during the development of
optical imaging in opaque tissues. Other possibilities may relate to
the study of hemodynamic response to light-generated oxygen
sinks and, possibly, also assistance to the blind.
METHODS
Tumor model
MADB106 rat mammary carcinoma cells were cultured in RPMI
medium, supplemented with 10% heat inactivated fetal calf serum,
1% non essential amino acids, 100 U/ml penicillin, 0.1 mg/ml
streptomycin, 0.25 mg/ml amphotericin B, 2 mM L-glutamine
and 1 mM pyruvate (Biological Industries, Kibbutz Beit Haemek,
Israel), in an atmosphere of 8% CO2 at 37uC. Cells (2610
6 cells in
60 ml saline) were grafted s.c. to the thigh of female Fisher rats and
the tumors were allowed to grow to treatment size of ,1 cm. All
protocols were approved by the Institutional Animal Care and Use
Committee.
Normal tissue model
The thigh quadriceps muscle of Wistar female rats was used as
a normal tissue model.
Anesthesia and experimental setup
Rats were anesthetized (i.p Ketamine 100 mg/kg, Diazepam
7.5 mg/kg), shaved and positioned supine/laterally above the
tumor or thigh, and the examined leg was fixed to the plexiglass
tray with adhesive tape to minimize motion artifacts.
Light source
Illumination was provided by a 1W, 755 nm diode laser, equipped
with a 3 mW aiming laser beam (660 nm) (CeramOptec, Germany).
Light was delivered with a cleaved bare optic fiber projecting a light
fieldof(w1 cm)withGaussianlightdistributionontotheskinoftherat
(Fig. 2). Alternatively, the light beam was delivered through a diffuser
(HoloOr, Rehovot, Israel), creating a circular (top hat cross section)
homogeneous light field (w 1.6 cm) on the animal’s skin (Fig. 3). Light
delivery to the treated rat inside the MRI magnet was remotely
controlled byan electronicinline shutter(Ocean Optics,Dunedin, Fl.
USA), gated with the magnetic resonance image scan acquisition.
Photosensitization protocol
The entire treatment protocol was conducted inside the MRI
magnet, where the anesthetized rat was placed in position (Fig. 1).
Sequential coronal gradient echo T2* weighted images, sensitive to
BOLD-contrast (40–60 images/experiment), were acquired during
the following four experimental steps: (i) Pretreatment Control
(PC); (ii) Light Control (LC) with illumination only. The target
tissue was illuminated from below the animal at the indicated
fluency rate and duration through a hole in the plexiglass tray
holding the rat; (iii) Photosensitization, triggered by bolus injection
into the tail vein of 10 mg/kg WST11, dissolved in saline, by
remote control through a previously placed catheter, while
illumination proceeded according to the preset paradigm indicated
in the individual experiments; and (iv) Post-illumination (PI),
during which the light is switched off.
Two illumination paradigms, synchronized with image acquisi-
tion, were used: P1, consisting of repeated light:dark periods
(12 s:110 s, a single image/light period); and P2, consisting of
continuous 600 s illumination (16 images/light period). The light
energies(2.4–33 J/cm
2)areindicatedforthe individualexperiments.
MRI set up
BOLD-contrast: Sequential coronal gradient echo T2* weighted
images, sensitive to BOLD-contrast, were acquired during all four
BOLD View of Light
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eter (Bruker, Germany) and a 7.5 cm volume coil with the
following parameters: Scan acquisition times (12 s or 25 s), as
indicated in the individual experiments, inter-scan time interval 9–
12 s, TR/TE/a 100 ms/10 ms/30u, in plane resolution 430 mm,
matrix 1286128, FOV 5.5 cm. Three slices (1.5 mm thickness)
were collected in tumor or muscle tissue. The data presented show
the slice positioned closest to, but just below the skin.
GdDTPA enhanced contrast
Following the VTP protocol, while the rat remained in position,
Gd-DTPA (0.1 mmol/kg, Magnevist, Schering, Berlin, Germany)
was injected i.v. to examine tumor vascularity, using the same
geometry as above with the following parameters: T1 weighted
spin echo sequence: TR/TE 140/9 ms, one scan. Due to its small
molecular weight, GdDTPA leaks from permeable vessels,
enhancing MRI signal from these areas.
Data Processing
In house programs for data processing were conducted with
Matlab 7.1 (The MathWork, Inc., Natik, MA.).
BOLD-contrast change maps: BOLD-contrast maps relative to
the average PC control baseline were calculated, pixel-by-pixel,
from sequential T2* weighted images (one map per time point,
total 40–60 per experiment, as indicated in the individual
experiments).
BOLD activation (%)=(1–BOLD image/average of BOLD
images in PC)6100.
In these experiments the loss in MR signal intensity is presented
as a gain in BOLD-contrast. Changes in BOLD-contrast maps are
color-coded according to the attached color scale in a range of 25
to +10%.
Correlation coefficient maps were extracted, by normalized,
pixel-by-pixel, correlation between the light paradigm and the
respective BOLD-contrast maps (calculated over the entire
experiment, 40–60 maps). The correlation coefficients are
presented in the interval of 0 to 1, where 1 stands for full
agreement between data and paradigm. Only correlation
coefficients that matched a p-value ,0.02 are displayed in the
maps. If the significance p(i,j) is small, then the correlation R(i,j) is
significant, so as to discard hazardous probability of synchrony. P-
values were calculated to test the hypothesis of no correlation. The
respective values in the maps were color-coded, according to the
attached color scale and overlaid on the anatomical image.
Contrast enhancement was calculated from the correlation
coefficient maps (p,0.02) as the ratio between densities of positive
pixels in the illuminated area and the rest of the image.
False positive pixels in the non-illuminated area refer to the
percentage of pixels that correlated with the paradigm (p,0.02)
outside the illuminated area.
Histology
Target tissues were excised from euthanized rats 24 h after
treatment, fixed in 3.8% formaldehyde, followed by standard
histological preparation and hematoxylin eosin staining. Patho-
logical evaluation was conducted by Dr. O. Brener, from the
Weizmann Institute Pathology Service Unit.
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